Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 1.00 |
| ▸ | CA7 | P43166 | 1/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392490 | 0.89 | TSHR (0.95) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL17339932 | 0.85 | CA12 (0.73) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL6950409 | 0.85 | CA12 (0.73) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL333915 | 0.85 | CA12 (0.73) | CA12CA7CA14TSHRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5000006 | 0.83 | CA12 (0.70) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL8263003 | 0.82 | CA12 (0.67) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL2430488 | 0.82 | CA12 (0.67) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL222875 | 0.79 | CA12 (0.65) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL490315 | 0.79 | CA12 (0.65) | CA12CA7CA14TSHRSMN1; SMN2 | |
| SCHEMBL898965 | 0.79 | CA12 (0.65) | CA12CA7CA14TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114727991-A | Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20220089584-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2022-03-24 | — | — | US | disclosed |
| CN-109069491-A | The positive allosteric modulators of mAChR M1 | 范德比尔特大学 | 2018-12-21 | — | — | CN | disclosed |
| US-10111884-B2 | Methods and compositions for treating viral infections | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2018-10-30 | — | — | US | disclosed |
| CN-105848654-B | Method and composition for treating cancer | 乔治城大学 | 2018-10-02 | — | — | CN | disclosed |
| CN-107847486-A | Salts and prodrugs of 1-methyl-D-tryptophan | 新联基因公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-103619446-B | The functionality electrodeposited coating reused on perforated membrane | 英派尔科技开发有限公司 | 2018-01-19 | — | — | CN | disclosed |
| CN-107567453-A | (base of indazole 4) hexahydropyrrolo and pyrrolones and application method | 艾伯维公司 | 2018-01-09 | — | — | CN | disclosed |
| EP-2838903-B1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS | UNIV HONG KONG SCIENCE & TECH (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-9616067-B2 | Methods and compositions for treating viral infections | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2017-04-11 | — | — | US | disclosed |
| CN-1149196-C | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | ����˹�ж�-����˹˹������˾ | 2004-05-12 | — | — | CN | disclosed |
| CN-1143855-C | I (ortho)-anthranilamide derivatives as anti-coagulants | ���ֹɷݹ�˾ | 2004-03-31 | — | — | CN | disclosed |
| CN-1111159-C | Thio acid-derived monocyclic N-heterocyclic compounds as anticoagulants | SCHERING AG (DE) | 2003-06-11 | — | — | CN | disclosed |
| CN-1348370-A | Cyclic protein tyrosine kinase inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2002-05-08 | — | — | CN | disclosed |
| CN-1329491-A | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants | BERLEX LAB (US) | 2002-01-02 | — | — | CN | disclosed |
| CN-1296486-A | Glucocorticoid-selective anti-inflammatory agents | ABBOTT LAB (US) | 2001-05-23 | — | — | CN | disclosed |
| CN-1282329-A | I (ortho)-anthranilamide derivatives as anti-coagulants | SCHERING AG (DE) | 2001-01-31 | — | — | CN | disclosed |
| CN-1233247-A | Thio acid-derived monocyclic N-heterocyclic compounds as anticoagulants | SCHERING AG (DE) | 1999-10-27 | — | — | CN | disclosed |
| CN-1120040-A | Identification and use of protease inhibitors | LILLY CO ELI (US) | 1996-04-10 | — | — | CN | disclosed |
| CN-1071917-A | Quinazoline derivant as human immunodeficiency virus reversed transcriptive enzyme antagonist | MERCK & CO INC (US) | 1993-05-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10111884-B2 | Methods and compositions for treating viral infections | MAVS, EIF2AK2, HAVCR2 | CA12 2878/4885CA7 2409/4885CA14 2219/4885 |
| US-20220089584-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | CA12 2519/4885CA7 1118/4885CA14 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.